L-Theanine-Caffeine Combination for Selective Attention in ADHD

1 Nawarathna et al. 2026 — L-Theanine-Caffeine Combo vs Methylphenidate for Selective Attention in Adolescent ADHD

(Nawarathna et al. 2026)

Full Citation:: Nawarathna GS, Ariyasinghe DI, Balasooriya N, Fernando A, Dassanayake TL. Effects of L-theanine-caffeine combination on selective attention among adolescents with attention-deficit hyperactivity disorder: a double-blind, placebo-controlled, crossover study. Nutritional Neuroscience. 2026:1-14. DOI:: 10.1080/1028415X.2026.2659148 PMID:: 42096377 Trial Registration:: SLCTR/2023/004 Study Design:: Double-blind, placebo-controlled, counterbalanced three-way crossover RCT Sample Size:: n=21 adolescents with ADHD (age 10-19; 18 boys) Key Findings::

  • L-theanine-caffeine combo (P=0.038) and methylphenidate (P=0.035) significantly reduced false alarms vs placebo on a computerized visual recognition reaction-time task.
  • Hits and discrimination sensitivity (A’) showed no significant differences (P>0.05).
  • Only methylphenidate improved reaction time vs placebo (mean difference 43.89 ms, P=0.018).
  • Both combo and methylphenidate increased P3b amplitude and decreased P3b latency (P<0.05), and counteracted reaction-time slowing over task duration. Conclusion:: High-dose L-theanine-caffeine may enhance neural resource allocation and speed of selective-attention deployment in adolescent ADHD, supporting nutraceutical adjunct use — but it did not match methylphenidate on reaction time. Limitations:: n=21 (small); acute single-dose only; adolescent ADHD cohort (not ME/CFS); predominantly male (18/21); no long-term safety data. Certainty Assessment:: 0.55 raw × 0.75 ADHD disease-model weight = discounted 0.41

2 Kahathuduwa et al. 2020 — L-Theanine-Caffeine Combo for Sustained Attention in Children with ADHD (Proof-of-Concept)

(Kahathuduwa et al. 2020)

Full Citation:: Kahathuduwa CN, Wakefield S, West BD, Blume J, Dassanayake TL, Weerasinghe VS, Mastergeorge A. Effects of L-theanine-caffeine combination on sustained attention and inhibitory control among children with ADHD: a proof-of-concept neuroimaging RCT. Scientific Reports. 2020;10(1):13072. DOI:: 10.1038/s41598-020-70037-7 PMID:: 32753637 Study Design:: Four-way repeated-measures crossover RCT with fMRI Sample Size:: n=5 boys with ADHD (age 8-15) Key Findings::

  • L-theanine alone improved NIH Cognition Toolbox total cognition composite (p=0.040) vs placebo.
  • Caffeine alone worsened inhibitory control (Stop-signal reaction time, p=0.031); L-theanine trended toward worsening (p=0.053).
  • Combination improved total cognition (p=0.041) and d-prime in Go/NoGo (p=0.033); decreased default-mode-network task reactivity. Conclusion:: Predecessor proof-of-concept to Nawarathna 2026 — combination is the active form, not the individual components; caffeine alone may harm inhibitory control. Limitations:: n=5 (very small); boys only; acute dosing. Certainty Assessment:: 0.40 raw × 0.75 ADHD disease-model weight = discounted 0.30

3 Al Shahab et al. 2025 — Supplements for ADHD: Systematic Review (Caffeine-Alone NULL)

(Al Shahab et al. 2025)

Full Citation:: Al Shahab S, Al Balushi R, Qambar A, Abdulla R, Qader M, Abdulla S, Jahrami H. Efficiency of Different Supplements in Alleviating Symptoms of ADHD with or Without the Use of Stimulants: A Systematic Review. Nutrients. 2025;17(9):1482. DOI:: 10.3390/nu17091482 PMID:: 40362791 Key Findings::

  • L-theanine improved sleep efficiency but not other sleep parameters.
  • Caffeine showed NO significant benefit alone; its combination with L-theanine may enhance attention.
  • Bacopa monnieri consistently improved inattention/hyperactivity/memory; Ginkgo biloba reduced inattention but was less effective than methylphenidate. Conclusion:: Supplements cannot replace stimulant efficacy for ADHD; caffeine’s attention benefit is dependent on L-theanine co-administration — a null/negative signal for caffeine monotherapy. Limitations:: Heterogeneous small studies; systematic review (no new data). Certainty Assessment:: 0.60 raw × 0.75 ADHD disease-model weight = discounted 0.45

4 Anas Sohail et al. 2021 — Cognitive-Enhancing Mechanisms of Caffeine and L-Theanine (MECHANISM)

(Anas Sohail et al. 2021)

Full Citation:: Anas Sohail A, Ortiz F, Varghese T, Fabara SP, Batth AS, Sandesara DP, Sabir A, Khurana M, Datta S, Patel UK. The Cognitive-Enhancing Outcomes of Caffeine and L-theanine: A Systematic Review. Cureus. 2021;13(12):e20828. DOI:: 10.7759/cureus.20828 PMID:: 35111479 Key Findings::

  • Caffeine inhibits adenosine A1/A2A receptors, augmenting attention via increased cholinergic and dopaminergic transmission.
  • L-theanine behaves as a glutamate reuptake inhibitor and competitive low-affinity glutamate receptor antagonist in hippocampus, with neuroprotective action on GABA-A receptors. Conclusion:: Documents the dual mechanistic basis — caffeine (adenosine antagonism) vs L-theanine (glutamate/GABA modulation) — for the combination’s attention effect. Limitations:: Low-impact journal (Cureus); review only, no new data. Certainty Assessment:: 0.45 raw × 0.75 general-population weight = discounted 0.34

5 Gerolymos et al. 2026 — L-Theanine Meta-Analysis: Attention Benefit, No Fatigue Effect (NULL fatigue)

(Gerolymos et al. 2026)

Full Citation:: Gerolymos C, Saddier E, Boyer L, Fond G. Cognitive and affective effects of L-Theanine: a systematic review and meta-analysis of 31 randomized trials. Molecular Psychiatry. 2026. Epub ahead of print. DOI:: 10.1038/s41380-026-03727-9 PMID:: 42410082 Key Findings::

  • Single 200 mg dose improved choice reaction time (SMD=0.51; 95% CI 0.25-0.77), indicating enhanced attention.
  • Acute stress reduction modest (SMD=0.31) and driven by high risk-of-bias studies.
  • NO significant effect on fatigue — the critical null for ME/CFS relevance.
  • No serious adverse events reported. Conclusion:: L-theanine is safe with a robust short-term attention benefit in healthy adults, but does not reduce fatigue — limiting its direct applicability to ME/CFS fatigue. Limitations:: Mostly healthy populations; fatigue outcome null; COI (Fond founded a supplement company). Certainty Assessment:: 0.80 raw × 0.75 general-population weight = discounted 0.60

6 Becker et al. 2022 — Stimulant Cognitive Enhancement Mechanism: FPN-DMN Decoupling (COMPETING MECHANISM)

(Becker et al. 2022)

Full Citation:: Becker M, Repantis D, Dresler M, Kühn S. Cognitive enhancement: Effects of methylphenidate, modafinil, and caffeine on latent memory and resting state functional connectivity in healthy adults. Human Brain Mapping. 2022;43(14):4225-4238. DOI:: 10.1002/hbm.25949 PMID:: 35670369 Study Design:: Double-blind RCT with resting-state fMRI Sample Size:: n=48 healthy male adults Key Findings::

  • Methylphenidate, modafinil, and caffeine all enhanced memory and modulated frontoparietal-network (FPN) vs default-mode-network (DMN) functional connectivity.
  • Decreased negative FPN-DMN connectivity predicted stimulant-induced latent memory enhancement. Conclusion:: Establishes a shared dopamine/network-level mechanism (FPN-DMN decoupling) for stimulant cognitive enhancement — the comparator mechanism against methylphenidate’s DAT blockade. Limitations:: Healthy males only; acute dosing. Certainty Assessment:: 0.70 raw × 0.75 general-population weight = discounted 0.53

7 Carbone et al. 2025 — Caffeine in Aging Brains: Tolerance, Withdrawal, Fatigue (HARM)

(Carbone et al. 2025)

Full Citation:: Carbone MG, Pagni G, Tagliarini C, Maremmani I, Maremmani AGI. Caffeine in Aging Brains: Cognitive Enhancement, Neurodegeneration, and Emerging Concerns About Addiction. International Journal of Environmental Research and Public Health. 2025;22(8):1171. DOI:: 10.3390/ijerph22081171 PMID:: 40869757 Key Findings::

  • Caffeine acts on central adenosine, dopamine, and glutamate systems, producing stimulating and rewarding effects that foster tolerance.
  • Chronic exposure induces adenosine receptor down-regulation → tolerance and withdrawal (headache, irritability, fatigue).
  • Excessive use may cause anxiety, sleep disturbance, and cognitive/motor impairment. Conclusion:: Documents caffeine use disorder and withdrawal-fatigue — the adenosine-receptor down-regulation mechanism that could mimic or exacerbate ME/CFS fatigue and sleep disruption. Limitations:: Narrative review; aging population (not ME/CFS). Certainty Assessment:: 0.45 raw × 0.75 general/aging weight = discounted 0.34

8 Srinivasan & Joseph 2026 — ATP-P2X3 Dysgeusia Hypothesis: Purinergic Bridge to ME/CFS (INDIRECT)

(Srinivasan and Joseph 2026)

Full Citation:: Srinivasan M, Joseph PV. A hypothesis connecting dysgeusia due to defects in ATP-P2X3 signaling and fatigue in myalgic encephalomyelitis/chronic fatigue syndrome: lessons learned from long-COVID. Frontiers in Medicine. 2026;13:1808646. DOI:: 10.3389/fmed.2026.1808646 PMID:: 42040552 Key Findings::

  • Proposes dysregulation of ATP signaling through P2X2/P2X3 purinergic receptors underlies both gustatory impairment and core ME/CFS symptoms (PEM, brain fog, autonomic dysregulation).
  • Positions chemosensory/taste dysfunction as an underrecognized ME/CFS feature; proposes standardized taste testing as a non-invasive PEM screening tool. Conclusion:: Indirect biochemical bridge — the P2X purinergic/adenosine signaling axis is the same downstream system caffeine antagonizes (adenosine A1/A2A receptors), linking caffeine’s adenosine mechanism to ME/CFS purinergic dysregulation. Limitations:: Hypothesis only, no primary data. Certainty Assessment:: 0.45 raw × 0.85 long-COVID/ME/CFS weight = discounted 0.38

9 Palacios et al. 2023 — ME/CFS vs Severe Fatigue Risk Factors: No Caffeine Association (NULL)

(Palacios et al. 2023)

Full Citation:: Palacios N, Molsberry S, Fitzgerald KC, Komaroff AL. Different risk factors distinguish myalgic encephalomyelitis/chronic fatigue syndrome from severe fatigue. Scientific Reports. 2023;13(1):2469. DOI:: 10.1038/s41598-023-29329-x PMID:: 36774379 Study Design:: Prospective cohort (Nurses’ Health Study) Sample Size:: n=41,802 female nurses (102 ME/CFS, 522 severe fatigue, 41,178 controls) Key Findings::

  • Severe fatigue risk increased with older age, higher BMI, hormone therapy, increased alcohol, and DECREASED caffeine intake.
  • These associations were NOT seen in ME/CFS — caffeine had no association with ME/CFS risk. Conclusion:: Key null/negative signal: caffeine’s inverse association with general fatigue does not extend to ME/CFS, cautioning against generalizing caffeine’s fatigue effects to the ME/CFS population. Limitations:: Female nurses only; diagnostic criteria for ME/CFS subset not fully specified; observational. Certainty Assessment:: 0.75 raw × 0.85 ME/CFS weight = discounted 0.64

10 Weigel et al. 2021 — Nutrition and Supplement Use in Australian ME/CFS (caffeine self-medication)

(Weigel et al. 2021)

Full Citation:: Weigel B, Eaton-Fitch N, Passmore R, Cabanas H, Staines D, Marshall-Gradisnik S. A preliminary investigation of nutritional intake and supplement use in Australians with myalgic encephalomyelitis/chronic fatigue syndrome and the implications on health-related quality of life. Food & Nutrition Research. 2021;65:5730. DOI:: 10.29219/fnr.v65.5730 PMID:: 34262415 Study Design:: Cross-sectional survey Sample Size:: n=24 Australian ME/CFS patients (54.2% ICC, 79.2% female) Key Findings::

  • Daily caffeine intake significantly HIGHER in ME/CFS patients than the Australian population (P=0.033).
  • Supplement use highly prevalent (87.5%); no consistent trends between nutrition/supplement use and HRQoL. Conclusion:: ME/CFS patients self-report elevated caffeine consumption (contrasting Palacios 2023), suggesting caffeine is used as fatigue self-medication without demonstrated HRQoL benefit. Limitations:: n=24 (very small); self-report; no efficacy outcome. Certainty Assessment:: 0.45 raw × 0.85 ME/CFS weight = discounted 0.38

11 Erasmus et al. 2019 — Caffeine as Phase-I Probe in Chronic Fatigue Biotransformation (INDIRECT)

(Erasmus et al. 2019)

Full Citation:: Erasmus E, Steffens FE, van Reenen M, Vorster BC, Reinecke CJ. Biotransformation profiles from a cohort of chronic fatigue women in response to a hepatic detoxification challenge. PLoS One. 2019;14(5):e0216298. DOI:: 10.1371/journal.pone.0216298 PMID:: 31075116 Study Design:: Seven-year metabolomics cohort study Sample Size:: n=576 women with low-to-high chronic fatigue Key Findings::

  • Hepatic detoxification challenge via oral caffeine (CYP1A2 phase-I probe), acetaminophen, and aspirin showed normal phase I but increased phase II glucuronidation and glycination conjugation.
  • Proposes fatigue-scale + medical symptoms + biotransformation profiles as a personalized diagnostic instrument. Conclusion:: Indirect biochemical link — caffeine metabolism (phase I) is directly tied to chronic-fatigue biotransformation, connecting caffeine handling to fatigue pathophysiology. Limitations:: Chronic fatigue (not strict ME/CFS criteria); all-female; no treatment outcome. Certainty Assessment:: 0.50 raw × 0.75 general chronic-fatigue weight = discounted 0.38

12 Wirth & Steinacker 2025 — Myasthenia and Fasciculations in Severely Ill ME/CFS (MUSCULAR hypothesis)

(Wirth and Steinacker 2025)

Full Citation:: Wirth KJ, Steinacker JM. The potential causes of myasthenia and fasciculations in severely ill ME/CFS patients: the role of disturbed electrophysiology. Frontiers in Physiology. 2025;16:1693589. DOI:: 10.3389/fphys.2025.1693589 PMID:: 41705124 Study Design:: Hypothesis/mechanistic review (no new empirical data) Sample Size:: n/a (hypothesis paper) Key Findings::

  • Proposes a MUSCULAR (sarcolemmal) mechanism for ME/CFS myasthenia, fasciculations, and cramps: Na+/K+-ATPase dysfunction → sarcolemmal depolarization → hyperexcitability.
  • Explicitly argues AGAINST a neuronal cause (“neurological investigations exclude neuronal causes”).
  • Connects to muscle sodium overload (see Petter 2022 23Na-MRI). Conclusion:: The only published ME/CFS-specific account of cramps/fasciculations favors a muscular-membrane mechanism, not a neurogenic one. Limitations:: Hypothesis only, no new data; COI (Wirth employed by Mitodicure GmbH); certainty low. Certainty Assessment:: 0.35 raw × 1.00 ME/CFS weight = discounted 0.35

13 Czesnik et al. 2015 — HCN Channel Hyperexcitability in Cramp-Fasciculation Syndrome (NEUROGENIC mechanism)

(Czesnik et al. 2015)

Full Citation:: Czesnik D, Howells J, Negro F, Wagenknecht H, Burke D, Bostock H. Increased HCN channel driven inward rectification in benign cramp fasciculation syndrome. Brain. 2015;138(Pt 11):3168-3179. DOI:: 10.1093/brain/awv250 PMID:: 26342125 Study Design:: Cross-sectional axonal excitability testing + modeling Sample Size:: n=20 cramp-fasciculation syndrome patients Key Findings::

  • Benign cramp-fasciculation syndrome shows increased HCN-channel inward rectification on axonal excitability testing.
  • Demonstrates a NEUROGENIC, ion-channel (HCN) mechanism for spontaneous muscle cramps and fasciculations. Conclusion:: In the general population, cramps can arise from motor-nerve-terminal hyperexcitability driven by ion channels — the default neurogenic model. Limitations:: General population, not ME/CFS; extrapolation to ME/CFS is untested. Certainty Assessment:: 0.70 raw × 0.75 general-population weight = discounted 0.53

14 Garrison et al. 2020 — Magnesium for Skeletal Muscle Cramps (Cochrane, NULL for ion-deficit)

(Garrison et al. 2020)

Full Citation:: Garrison SR, Korownyk CS, Kolber MR, Allan GM, Musini VM, Sekhon RK, Dugré N. Magnesium for skeletal muscle cramps. Cochrane Database of Systematic Reviews. 2020;(9):CD009402. DOI:: 10.1002/14651858.CD009402.pub3 PMID:: 32956536 Study Design:: Systematic review / meta-analysis (11 RCTs) Sample Size:: n=735 Key Findings::

  • Magnesium does NOT prevent or relieve muscle cramps (idiopathic cramps).
  • Null result directly undercuts the “magnesium deficiency causes cramps” (ion-deficit) model. Conclusion:: Magnesium supplementation is ineffective for cramps — supporting that cramps are not a simple ion-deficit problem. Limitations:: Idiopathic/general cramps, not ME/CFS-specific; largely older adults. Certainty Assessment:: 0.85 raw × 0.75 general-population weight = discounted 0.64

15 Maughan & Shirreffs 2019 — Muscle Cramping: Causes, Solutions, Remaining Questions

(Maughan and Shirreffs 2019)

Full Citation:: Maughan RJ, Shirreffs SM. Muscle Cramping During Exercise: Causes, Solutions, and Questions Remaining. Sports Medicine. 2019;49(Suppl 2):115-124. DOI:: 10.1007/s40279-019-01162-1 PMID:: 31696455 Study Design:: Narrative review Sample Size:: n/a (review) Key Findings::

  • Cramps involve “sustained abnormal spinal reflex activity secondary to fatigue.”
  • Integrates neurogenic (motor-neuron/spinal) mechanisms of cramp generation. Conclusion:: Supports a neurogenic/spinal-reflex component to cramps, distinct from a purely muscular energy-deficit account. Limitations:: General exercise physiology, not ME/CFS; not a mechanism in patients at rest. Certainty Assessment:: 0.60 raw × 0.75 general-population weight = discounted 0.45

16 Craighead et al. 2017 — TRP Agonists Attenuate Exercise-Induced Muscle Cramps

(Craighead et al. 2017)

Full Citation:: Craighead DH, Shank SW, Gottschall JS, Passe DH, Murray B, Bassett DR, Alexander LM. Ingestion of transient receptor potential channel agonists attenuates exercise-induced muscle cramps. Muscle & Nerve. 2017;56:379-385. DOI:: 10.1002/mus.25611 PMID:: 28192854 Study Design:: Crossover experimental study Sample Size:: n=39 Key Findings::

  • Ingestion of TRP-channel agonists (TRPV1/TRPA1) attenuates exercise-induced muscle cramps.
  • Demonstrates that sensory-nerve TRP channels can gate motor-neuron cramp excitability. Conclusion:: TRP-channel modulation can influence cramp threshold — a plausible link between ion-channel function and cramp generation. Limitations:: Healthy humans, exercise-induced cramps; not ME/CFS spontaneous cramps. Certainty Assessment:: 0.55 raw × 0.75 general-population weight = discounted 0.41

17 Lopate et al. 2013 — Cramps and Small-Fiber Neuropathy

(Lopate et al. 2013)

Full Citation:: Lopate G, Streif E, Harms M, Al-Lozi M, Pestronk A. Cramps and small-fiber neuropathy. Muscle & Nerve. 2013;48(2):252-255. DOI:: 10.1002/mus.23759 PMID:: 23813593 Study Design:: Cross-sectional cohort Sample Size:: n=12 cramp patients Key Findings::

  • 60% of patients presenting with cramps have small-fiber neuropathy.
  • Suggests cramps may originate from damaged small-nerve mediators exciting intramuscular nerves. Conclusion:: SFN is directly associated with cramps in the general population — a bridge to the documented ME/CFS SFN finding. Limitations:: General population; small n; not ME/CFS-specific. Certainty Assessment:: 0.50 raw × 0.75 general-population weight = discounted 0.38

18 Koopmans et al. 2019 — SynGO: Evidence-Based Expert-Curated Synapse Knowledge Base

(Koopmans et al. 2019)

Full Citation:: Koopmans F, van Nierop P, Andres-Alonso M, et al. SynGO: An Evidence-Based, Expert-Curated Knowledge Base for the Synapse. Neuron. 2019;103(2):217-234.e4. DOI:: 10.1016/j.neuron.2019.05.002 PMID:: 31171447 Study Design:: Knowledge-base construction (expert curation + Gene Ontology annotation) Sample Size:: 2,922 annotations for 1,112 genes; 87 synaptic locations + 179 synaptic processes Key Findings::

  • Synaptic genes are exceptionally conserved and less tolerant to loss-of-function mutations than other genes.
  • SynGO terms significantly overrepresented among gene variants for intelligence, educational attainment, ADHD, autism, bipolar disorder, and neurodevelopmental-disorder de novo variants (incl. schizophrenia).
  • Provides the public analysis platform (syngoportal.org) used for the SynGO MAGMA enrichment applied to DecodeME/MVP GWAS. Conclusion:: Establishes SynGO as the reference synapse ontology — the tooling that makes “synaptic gene-ontology enrichment in ME/CFS” interpretable and reproducible. Limitations:: Not a patient study; a reference resource. Requires external GWAS/summary statistics as input. Certainty Assessment:: 0.85 raw × 0.30 in-silico weight = discounted 0.26 (tooling/grounding, not a patient finding)

19 Onwordi et al. 2020 — SV2A Synaptic-Density Marker Reduced in Schizophrenia

(Onwordi et al. 2020)

Full Citation:: Onwordi EC, Halff EF, Whitehurst T, et al. Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats. Nature Communications. 2020;11(1):246. DOI:: 10.1038/s41467-019-14122-0 PMID:: 31937764 Study Design:: Case-control in-vivo PET + rat pharmacology validation Sample Size:: n=18 schizophrenia, n=18 controls; Sprague-Dawley rats for antipsychotic arm Key Findings::

  • [11C]UCB-J SV2A binding significantly lower in frontal and anterior cingulate cortices in schizophrenia (Cohen’s d=0.8-0.9); hippocampus unchanged.
  • Antipsychotic drug exposure does not alter SV2A levels (western blot, autoradiography, immunostaining). Conclusion:: Establishes in-vivo SV2A PET as a synaptic-terminal-density readout; the precedent for the proposed SV2A imaging step in ME/CFS. Limitations:: Schizophrenia cohort, not ME/CFS; cross-sectional; n=18 per group. Certainty Assessment:: 0.75 raw × 0.50 other-disease weight = discounted 0.38

20 Onwordi et al. 2021 — SV2A Relates to Glutamate in Health, Not Schizophrenia

(Onwordi et al. 2021)

Full Citation:: Onwordi EC, Whitehurst T, Mansur A, et al. The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia. Translational Psychiatry. 2021;11(1):393. DOI:: 10.1038/s41398-021-01515-3 PMID:: 34282130 Study Design:: Multimodal PET + 1H-MRS imaging Sample Size:: n=40 (18 schizophrenia, 22 healthy volunteers) Key Findings::

  • SV2A DVR positively correlated with Glu/Cr and Glx/Cr in healthy volunteers, in both hippocampus and ACC.
  • This coupling was absent in schizophrenia — the MRS glutamatergic signal tracks synaptic density in health but not disease.
  • No relationship between SV2A and NAA in either group. Conclusion:: An appreciable proportion of the brain glutamatergic MRS signal reflects synaptic density — linking the synaptic-genetic signal to a measurable in-vivo glutamatergic correlate. Limitations:: Schizophrenia/HV; COI disclosed (Invicro employees, Lundbeck involvement); n=40. Certainty Assessment:: 0.70 raw × 0.50 other-disease weight = discounted 0.35

21 Asch et al. 2024 — In-Vivo Synaptic Density Imaging and Depression (SV2A review)

(Asch et al. 2024)

Full Citation:: Asch RH, Abdallah CG, Carson RE, Esterlis I. Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression. Neuropsychopharmacology. 2024;50(1):153-163. DOI:: 10.1038/s41386-024-01913-3 PMID:: 39039139 Study Design:: Review (tracer development + quantification methods + depression application) Sample Size:: n/a (review) Key Findings::

  • Documents SV2A tracer development ([11C]UCB-J, [18F]SynVesT-1) and quantification approaches.
  • Lower SV2A synaptic density in depressive symptoms; ketamine drug challenge used to image synaptogenesis in vivo.
  • Reviews translational animal-model SV2A imaging and methodological challenges. Conclusion:: SV2A PET is the mature in-vivo synaptic-density method for neuropsychiatric disorders — the imaging platform a SynGO-in-ME/CFS study would deploy. Limitations:: Review; COI — R.E.C. inventor on [18F]SynVesT-1 patent, C.G.A. industry consulting. Certainty Assessment:: 0.70 raw × 0.75 general-population weight = discounted 0.53

22 Serrano et al. 2022 — Imaging Synaptic Density (methodology review)

(Serrano et al. 2022)

Full Citation:: Serrano ME, Kim E, Petrinovic MM, Turkheimer F, Cash D. Imaging Synaptic Density: The Next Holy Grail of Neuroscience? Frontiers in Neuroscience. 2022;16:796129. DOI:: 10.3389/fnins.2022.796129 PMID:: 35401097 Study Design:: Critical methodological review Sample Size:: n/a (review) Key Findings::

  • Compares ex-vivo (EM, immunohistochemistry) vs in-vivo (SV2A PET) vs MR-based (glutamate-linked) synaptic-density quantification.
  • SV2A PET tracers have limited specificity; MR glutamate approaches are non-invasive alternatives.
  • All methods entail trade-offs before routine clinical use. Conclusion:: Provides the methodological caveats (SV2A limited specificity) that must temper any proposed ME/CFS synaptic-density PET study. Limitations:: Review; no primary data. Certainty Assessment:: 0.60 raw × 0.75 general-population weight = discounted 0.45

23 Thapaliya et al. 2024 — Elevated Brain Glutamate in ME/CFS and Long COVID (MRS)

(Thapaliya, Marshall-Gradisnik, Eaton-Fitch, et al. 2025)

Full Citation:: Thapaliya K, Marshall-Gradisnik S, Eaton-Fitch N, Eftekhari Z, Inderyas M, Barnden L. Imbalanced Brain Neurochemicals in Long COVID and ME/CFS: A Preliminary Study Using MRI. The American Journal of Medicine. 2025;138(3):567-574.e1. DOI:: 10.1016/j.amjmed.2024.04.007 PMID:: 38588934 Study Design:: Cross-sectional 3T MRS (posterior cingulate cortex) Sample Size:: n=17 ME/CFS, n=17 Long COVID, n=10 healthy controls Key Findings::

  • Glutamate significantly higher in ME/CFS (P=.017) and Long COVID (P=.02) vs healthy controls.
  • NAA significantly higher in Long COVID only.
  • No ME/CFS vs Long COVID difference — suggesting shared neurochemical pathology. Conclusion:: First ME/CFS-specific in-vivo evidence of elevated brain glutamate — a direct biochemical correlate of the glutamatergic-synaptic genetic signal (Maccallini 2026 / SynGO enrichment). Limitations:: Small n; single center (Griffith NCNED); posterior cingulate only; preliminary. Certainty Assessment:: 0.55 raw × 1.00 ME/CFS weight = discounted 0.55

24 Williams et al. 2019 — EBV dUTPase Alters Synaptic-Plasticity Genes (ME/CFS)

(Williams et al. 2019)

Full Citation:: Williams MV, Cox B, Lafuse WP, Ariza ME. Epstein-Barr Virus dUTPase Induces Neuroinflammatory Mediators: Implications for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Clinical Therapeutics. 2019;41(5):848-863. DOI:: 10.1016/j.clinthera.2019.04.009 PMID:: 31040055 Study Design:: In vitro (astrocytes/microglia/endothelial) + in vivo mouse Sample Size:: 12/15 genes in vitro; 34/84 genes in vivo; female C57Bl/6 mice Key Findings::

  • EBV dUTPase protein altered expression of genes controlling blood-brain-barrier integrity and synaptic plasticity.
  • Affected pain-synapse structure/function and dopamine/serotonin/GABA/glutamate pathways.
  • dUTPase seropositive in 30.91-52.7% of ME/CFS patients (prior cohorts). Conclusion:: Mechanistic bridge from a documented ME/CFS viral trigger (EBV) to altered synaptic-plasticity gene expression — connecting the infection-trigger narrative to the synaptic-genetic enrichment signal. Limitations:: In vitro + animal; no human synaptic-plasticity gene measurement; OH State group line. Certainty Assessment:: 0.55 raw × 0.50 in-vitro/animal weight = discounted 0.28

25 Wang et al. 2021 — Glutamate in Gulf War Illness (cross-disease glutamatergic synapse)

(Wang, Ali, and Lin 2021)

Full Citation:: Wang X, Ali N, Lin CG. Emerging role of glutamate in the pathophysiology and therapeutics of Gulf War illness. Life Sciences. 2021;280:119609. DOI:: 10.1016/j.lfs.2021.119609 PMID:: 33991547 Study Design:: Review (cross-disease glutamatergic-synapse precedent) Sample Size:: n/a (review) Key Findings::

  • GWI rodent models show elevated extracellular glutamate and impaired glutamatergic synapse structure/function.
  • Restoring glutamatergic synapses ameliorates GWI pathological and behavioral deficits.
  • Low-glutamate diet reduced multiple GWI symptoms in veterans. Conclusion:: A glutamatergic-synaptic mechanism is translationally plausible in chronic fatigue/multisymptom illness — complementing the ME/CFS synaptic-genetic signal. Limitations:: Gulf War Illness, not ME/CFS; largely preclinical. Certainty Assessment:: 0.55 raw × 0.80 cross-disease weight = discounted 0.44

26 Fleury et al. 2026 — Encapsulated Leptin-Producing Cells Facilitate Circadian Entrainment (TRIGGER, INDIRECT)

(Fleury et al. 2026)

Full Citation:: Fleury ST, Lin X, Rios PD, Olker C, Song EJ, Perez AC, Fell C, Lopez D, Joshi I, Nasir H, Curtis C, Muringi D, Wang K, Oberholzer J, Turek FW, Hilton IB, Rivnay J, Vitaterna MH, Veiseh O. Encapsulated Leptin-Producing Cells Facilitate Entrainment of Circadian Rhythms in Rodents and Nonhuman Primates. Advanced Science. 2026;e77191. DOI:: 10.1002/advs.77191 PMID:: 42593855 Study Design:: Preclinical interventional (mouse + diurnal cynomolgus macaque) Sample Size:: mice + NHP (per-animal n not fully specified in abstract) Key Findings::

  • Subcutaneous “leptin factory” (encapsulated human RPE cells constitutively producing leptin) yields sustained blood-leptin elevation >1 day.
  • Accelerates re-entrainment to BOTH phase delays and phase advances.
  • In diurnal cynomolgus macaques: safe, reduces entrainment time by ~1 day.
  • No adverse sleep effect — increases NREM slow-wave energy. Conclusion:: Metabolic (leptin) regulation is a novel lever for accelerating circadian adaptation — the first demonstration that a metabolic signal can be engineered to speed entrainment. INDIRECT relevance to ME/CFS (no ME/CFS cohort); bears on the metabolic→circadian modulation mechanism underlying ME/CFS circadian/sleep-wake instability. Limitations:: Preclinical only; entrainment-speed endpoint not clinical symptom endpoint; no human or ME/CFS data. Certainty Assessment:: 0.55 raw × 0.50 animal-model weight = discounted 0.28

27 Tang et al. 2023 — DMH Leptin-Receptor Neurons Input to the Circadian Feeding Network (MECHANISM)

(Tang et al. 2023)

Full Citation:: Tang Q, Godschall E, Brennan CD, Zhang Q, Abraham-Fan RJ, Williams SP, Gungul TB, Onoharigho R, Buyukaksakal A, Salinas R, Sajonia IR, Olivieri JJ, Calhan OY, Deppmann CD, Campbell JN, Podyma B, Guler AD. Leptin receptor neurons in the dorsomedial hypothalamus input to the circadian feeding network. Science Advances. 2023;9(34):eadh9570. DOI:: 10.1126/sciadv.adh9570 PMID:: 37624889 Study Design:: Mechanistic (single-nucleus RNAseq + chemogenetic, mouse) Sample Size:: mouse (per-condition n not specified in abstract) Key Findings::

  • DMH LepR neurons up-regulate circadian entrainment genes and fire before anticipated meals.
  • Exogenous leptin, silencing, or chemogenetic activation disrupts food entrainment.
  • A DMH LepR subpopulation projects to the SCN and can shift clock phase — the direct metabolic→circadian integration circuit. Conclusion:: Provides the molecular substrate for the Fleury 2026 lever: metabolic state (leptin) can gate SCN clock phase via DMH LepR projection neurons. Limitations:: Mouse only; no human/ME/CFS translation. Certainty Assessment:: 0.75 raw × 0.50 animal-model weight = discounted 0.38

28 Faber et al. 2021 — Leptin-Receptor Neurons Regulate Diurnal Feeding and Metabolism (MECHANISM)

(Faber et al. 2021)

Full Citation:: Faber CL, Deem JD, Phan BA, Doan TP, Ogimoto K, Mirzadeh Z, Schwartz MW, Morton GJ. Leptin receptor neurons in the dorsomedial hypothalamus regulate diurnal patterns of feeding, locomotion, and metabolism. eLife. 2021;10:e63671. DOI:: 10.7554/eLife.63671 PMID:: 33527893 Study Design:: Mechanistic (viral silencing, mouse) Sample Size:: mouse (per-condition n not specified in abstract) Key Findings::

  • Silencing DMH LepR neurons increases body weight/adiposity, phase-advances diurnal feeding/metabolism into the light cycle.
  • Abolishes dark-cycle locomotor activity and prevents entrainment to restricted food availability. Conclusion:: DMH LepR neurons are critical determinants of daily feeding time and metabolic rhythms — the cell type the leptin-circadian pathway acts through. Limitations:: Mouse only; no disease model. Certainty Assessment:: 0.70 raw × 0.50 animal-model weight = discounted 0.35

29 Osorio-Mendoza et al. 2025 — Circadian Gating of Leptin Signalling (MECHANISM, bidirectional)

(Osorio-Mendoza et al. 2025)

Full Citation:: Osorio-Mendoza J, Kiehn JT, Stenger S, Heinen KO, Griewahn L, Koch CE, Haferkamp U, Pilorz V, Barclay JL, Joshi P, Harder L, Johren O, Kuhnen P, Eichele G, Oster H. Regulation of hedonic feeding rhythms by circadian clocks in leptin-receptive neurons. Molecular Metabolism. 2025;100:102221. DOI:: 10.1016/j.molmet.2025.102221 PMID:: 40714221 Study Design:: Mechanistic (ob/ob, Per1/2 KO, ObRb.Bmal1 mice) Sample Size:: mouse (per-genotype n not specified in abstract) Key Findings::

  • Leptin-deficient mice show increased hedonic appetite in early rest phase.
  • Clock-deficient Per1/2 mutants show blunted homeostatic + hedonic appetite rhythms.
  • CNS-specific ObRb.Bmal1 disruption lowers palatable-food sensitivity and blunts obesogenic weight gain. Conclusion:: The clock reciprocally gates leptin’s actions — bidirectional metabolic↔︎circadian coupling, cautioning that raising leptin in a desensitized/leptin-resistant state may not entrain. Limitations:: Mouse only. Certainty Assessment:: 0.70 raw × 0.50 animal-model weight = discounted 0.35

30 Cleare et al. 2001 — Plasma Leptin in CFS: No Baseline Difference (NULL)

(Cleare, O’Keane, and Miell 2001)

Full Citation:: Cleare AJ, O’Keane V, Miell J. Plasma leptin in chronic fatigue syndrome and a placebo-controlled study of the effects of hydrocortisone. Clinical Endocrinology. 2001;55(1):113-119. DOI:: 10.1046/j.1365-2265.2001.01341.x PMID:: 11453960 Study Design:: Case-control + randomized placebo-controlled crossover Sample Size:: n=32 CFS + 32 matched controls Key Findings::

  • NO significant difference in 0900h plasma leptin (CFS 13.8 vs control 10.2 ng/ml).
  • Hydrocortisone 10 mg (not 5 mg) raised leptin; rise greater in treatment responders (glucocorticoid-receptor-sensitivity signal, not a leptin-CFS causal link). Conclusion:: The only completed controlled human measurement of plasma leptin in CFS is NULL at baseline — the hormone shows no CFS-specific abnormality, weakening the case that a leptin intervention targets a primary CFS deficit. Limitations:: Single morning sample (no circadian sampling); n=32; dated (2001). Certainty Assessment:: 0.70 raw × 1.00 ME/CFS weight = discounted 0.70

31 Musker et al. 2021 — Circulating Leptin in ME/CFS: Systematic Review Protocol (NULL/GAP)

(Musker et al. 2021)

Full Citation:: Musker M, McArthur A, Munn Z, Wong ML. Circulating leptin levels in patients with myalgic encephalomyelitis, chronic fatigue syndrome or fibromyalgia: a systematic review protocol. JBI Evidence Synthesis. 2021;19(3):695-701. DOI:: 10.11124/JBIES-20-00125 PMID:: 33136710 Study Design:: Systematic review protocol (PROSPERO CRD42020169903) Sample Size:: n/a (protocol) Key Findings::

  • Protocol to evaluate circulating leptin in ME/CFS/fibromyalgia vs controls.
  • NO results published as of 2026 — no completed meta-analysis exists. Conclusion:: Documents the evidence GAP: despite mechanistic interest, there is no pooled human estimate of circulating leptin in ME/CFS. Limitations:: Protocol only; no data. Certainty Assessment:: 0.30 raw × 0.85 long-COVID/ME/CFS weight = discounted 0.26

32 Domingo et al. 2024 — Elevated Leptin in ME/CFS (DIRECTION-OF-EFFECT CAUTION)

(Domingo et al. 2024)

Full Citation:: Domingo JC, Battistini F, Cordobilla B, Zaragoza MC, Sanmartin-Sentanes R, Alegre-Martin J, Cambras T, Castro-Marrero J. Association of circulating biomarkers with illness severity measures differentiates myalgic encephalomyelitis/chronic fatigue syndrome and post-COVID-19 condition: a prospective pilot cohort study. Journal of Translational Medicine. 2024;22(1):343. DOI:: 10.1186/s12967-024-05148-0 PMID:: 38600563 Study Design:: Prospective cross-sectional pilot cohort Sample Size:: n=31 ME/CFS, 23 long COVID, 31 matched sedentary controls Key Findings::

  • ME/CFS patients had significantly HIGHER circulating leptin than controls (p<0.001), alongside elevated ET-1, VCAM-1, PAI-1, E-selectin, TNF-α, IL-1β, IL-4, IL-6, IL-10, IP-10 and lower nitrites. Conclusion:: A “leptin factory” would RAISE a hormone already ELEVATED in ME/CFS — opposite to a plausible therapeutic direction, and the target tissue may be leptin-resistant. Central caution for integrating Fleury 2026. Limitations:: Pilot (n=31); cross-sectional; single site; no circadian sampling. Certainty Assessment:: 0.65 raw × 1.00 ME/CFS weight = discounted 0.65

33 Cambras et al. 2026 — Light Exposure Patterns in ME/CFS (COMPETING/CONTEXT)

(Cambras et al. 2026)

Full Citation:: Cambras T, Domingo JC, Sanmartin-Sentanes R, Alegre-Martin J, Castro-Marrero J. Association between light exposure patterns and multidimensional health outcomes in individuals with myalgic encephalomyelitis/chronic fatigue syndrome: findings from an observational cross-sectional cohort study. Journal of Translational Medicine. 2026. doi:10.1186/s12967-026-08556-6. DOI:: 10.1186/s12967-026-08556-6 PMID:: 42399727 Study Design:: Observational cross-sectional cohort (1-week wrist actigraphy) Sample Size:: n=100 ME/CFS + 56 healthy controls Key Findings::

  • Light variables more strongly associated with clinical outcomes (FIS-40, PSQI, SF-36) in ME/CFS than controls.
  • Nocturnal/rhythm-instability light pattern (PC2) associated with higher VCAM-1 + triglycerides, lower serotonin.
  • Healthy-light pattern = lower fatigue, fewer sleep complaints. Conclusion:: Positions LIGHT (environmental zeitgeber), not metabolic/leptin signalling, as the dominant circadian lever in ME/CFS — a competing/complementary route to the Fleury 2026 metabolic mechanism. Limitations:: Cross-sectional; association not causation; light self-exposure confounded by behavior. Certainty Assessment:: 0.65 raw × 1.00 ME/CFS weight = discounted 0.65

34 Mukherjee et al. 2026 — Islet Encapsulation: Clinical-Translation Barriers (HARM/TECHNOLOGY)

(Mukherjee et al. 2026)

Full Citation:: Mukherjee S, Mandal S, Oberholzer J, Veiseh O. Type 1 Diabetes and Islet Encapsulation: From Historical Milestones to Cutting-Edge Advances. Annual Review of Biomedical Engineering. 2026;28(1):187-217. DOI:: 10.1146/annurev-bioeng-110824-024435 PMID:: 41609637 Study Design:: Review (technology/clinical translation) Sample Size:: n/a (review) Key Findings::

  • Biomaterial encapsulation addresses immune rejection and hypoxia, providing cell microenvironment and viability.
  • Documents clinical-translation barriers (immune rejection, foreign-body response, hypoxia) any encapsulated-cell “leptin factory” would also face before human use. Conclusion:: Technology-safety precedent for the Fleury 2026 approach (shared senior author Veiseh) — the encapsulation platform is validated in T1D but carries unresolved barriers for human translation. Limitations:: Review; T1D context (not ME/CFS); no safety-outcome data specific to leptin production. Certainty Assessment:: 0.60 raw × 0.30 other-disease weight = discounted 0.18

35 Thapaliya et al. 2025 — Altered Brain Microstructure and Neurochemicals in Long COVID and Recovered COVID-19 (Multimodal MRI)

(Thapaliya, Marshall-Gradisnik, Inderyas, et al. 2025)

Full Citation:: Thapaliya K, Marshall-Gradisnik S, Inderyas M, Barnden L. Altered brain tissue microstructure and neurochemical profiles in long COVID and recovered COVID-19 individuals: a multimodal MRI study. Brain, Behavior, & Immunity - Health. 2025;50:101142. DOI:: 10.1016/j.bbih.2025.101142 PMID:: 41404601 Study Design:: Cross-sectional multimodal 3T MRI (T1w/T2w ratio myelin mapping + DTI + single-voxel 1H-MRS in posterior cingulate cortex) Sample Size:: n=47 (long COVID=19 WHO-criteria; COVID-recovered healthy controls=12; healthy controls without COVID=16) Key Findings::

  • T1w/T2w (myelin proxy) higher in long COVID vs Non-COVID-HC in precentral gyrus (pfdr<0.001) and middle temporal gyrus (pfdr=0.005); higher in COVID-RHC vs long COVID in pons, midbrain, cerebellar tonsil, superior longitudinal fasciculus, precentral gyrus, forceps minor, optic radiation, Brodmann area 18; higher in COVID-RHC vs Non-COVID-HC in precentral gyrus and posterior cingulate.
  • T1w/T2w in middle temporal gyrus positively correlated with physical function (p=0.024, r=0.56); midbrain T1w/T2w negatively correlated with cognitive score (p=0.01, r=-0.64).
  • DTI: lower mean diffusivity in dentate regions (long COVID vs Non-COVID-HC, pfdr=0.041); higher fractional anisotropy in right superior longitudinal fasciculus (long COVID vs COVID-RHC, pfdr=0.001); lower AD/MD/RD in left caudate and lower AD in right supramarginal gyrus (COVID-RHC vs Non-COVID-HC).
  • MRS: only long COVID vs COVID-RHC differed after FDR correction — NAA higher in long COVID (pfdr=0.009); glutamine higher in COVID-RHC (pfdr=0.019); choline (higher in COVID-RHC) did not survive correction. Conclusion:: First study to report differential myelin-signal and neurochemical changes across long COVID, COVID-recovered, and uninfected controls. Authors interpret elevated T1w/T2w as possible remyelination, but explicitly caution it may instead reflect inflammation or gliosis. Establishes that even “recovered” COVID individuals retain measurable brain microstructure/neurochemical alterations. Limitations:: Cross-sectional; small n (n=47 total, subgroups 12-19); exploratory cluster threshold may inflate Type I error; single lab (Griffith NCNED); T1w/T2w direction ambiguous (myelin vs iron vs gliosis); no longitudinal follow-up. Certainty Assessment:: 0.55 raw × 0.85 long-COVID/post-viral weight = discounted 0.47

36 Thapaliya et al. 2020 — T1w/T2w Ratio Mapping in ME/CFS (Methodological Precursor)

(Thapaliya et al. 2020)

Full Citation:: Thapaliya K, Marshall-Gradisnik S, Staines D, Barnden L. Mapping of pathological change in chronic fatigue syndrome using the ratio of T1- and T2-weighted MRI scans. NeuroImage: Clinical. 2020;28:102366. DOI:: 10.1016/j.nicl.2020.102366 PMID:: 32777701 Study Design:: Cross-sectional T1w/T2w ratio mapping (whole-brain, region- and voxel-based) Sample Size:: n=45 ME/CFS (Fukuda) + 27 healthy controls Key Findings::

  • Elevated T1w/T2w (increased myelin and/or iron) in both white matter and subcortical grey matter in ME/CFS; no areas of decreased T1w/T2w.
  • Abnormal T1w/T2w regressions with heart-rate variability, cognitive performance, respiration rate, and physical wellbeing. Conclusion:: The T1w/T2w method is sensitive to microstructural change in ME/CFS. Same Griffith lab and method as the primary paper — anchors the 2025 long-COVID T1w/T2w finding to a prior ME/CFS finding from the same group. Limitations:: Single lab; Fukuda criteria (broad); cross-sectional; direction (myelin vs iron) ambiguous. Certainty Assessment:: 0.55 raw × 1.00 ME/CFS weight = discounted 0.55

37 Thapaliya et al. 2021 — DTI Microstructural Changes in ME/CFS

(Thapaliya et al. 2021)

Full Citation:: Thapaliya K, Marshall-Gradisnik S, Staines D, Barnden L. Diffusion tensor imaging reveals neuronal microstructural changes in myalgic encephalomyelitis/chronic fatigue syndrome. European Journal of Neuroscience. 2021;54(6):6214-6228. DOI:: 10.1111/ejn.15413 PMID:: 34355438 Study Design:: Cross-sectional DTI (voxel-based group comparison + interaction-with-group regression) Sample Size:: n=25 ME/CFS (Fukuda) + 18 ME/CFS (ICC) + 26 healthy controls Key Findings::

  • ME/CFS-ICC vs HC: decreased axial diffusivity (p=0.001) and mean diffusivity (p=0.01) in descending cortico-cerebellar tract (midbrain/pons); increased transverse diffusivity in medulla; decreased mode of anisotropy in superior longitudinal fasciculus.
  • Fukuda-only comparisons did not reach significance — strict case definition matters for detecting microstructural signal. Conclusion:: DTI is sensitive to ME/CFS microstructural change, particularly in brainstem/midbrain and superior longitudinal fasciculus; the same regions (midbrain, SLF) feature prominently in the 2025 long-COVID primary paper. Limitations:: Single lab (Griffith); small n; cross-sectional. Certainty Assessment:: 0.50 raw × 1.00 ME/CFS weight = discounted 0.50

38 Singh et al. 2026 — DTI + DKI Microstructural Alterations in ME/CFS and Long COVID

(Singh et al. 2026)

Full Citation:: Singh TB, Marshall-Gradisnik S, Barnden L, Eaton-Fitch N, Huynh TH, Inderyas M, Thapaliya K. Microstructural alterations in brain tissue of ME/CFS and long COVID using diffusion tensor imaging and diffusion kurtosis imaging. Frontiers in Medicine. 2026;13:1824498. DOI:: 10.3389/fmed.2026.1824498 PMID:: 42539798 Study Design:: Cross-sectional DTI + diffusion kurtosis imaging (3T Prisma) Sample Size:: n=37 ME/CFS + 19 long COVID + 27 healthy controls Key Findings::

  • ME/CFS vs HC: microstructural alterations in cingulum, supplementary motor areas, corpus callosum.
  • Long COVID vs HC: alterations in fusiform and precentral gyrus and major white-matter tracts.
  • Direct ME/CFS vs long COVID comparison: difference in left corona radiata (p=0.001). Conclusion:: Distinct tissue microstructural alterations in ME/CFS vs long COVID despite shared symptoms; extends the primary paper’s DTI arm with DKI and a direct cross-disease comparison from the same cohort registry. Limitations:: Same Griffith lab (not independent of primary); small subgroup n; cross-sectional. Certainty Assessment:: 0.50 raw × 0.85 long-COVID/post-viral weight = discounted 0.43

39 Maksoud et al. 2020 — Systematic Review of Neuroimaging in ME/CFS

(Maksoud et al. 2020)

Full Citation:: Maksoud R, du Preez S, Eaton-Fitch N, Thapaliya K, Barnden L, Cabanas H, Staines D, Marshall-Gradisnik S. A systematic review of neurological impairments in myalgic encephalomyelitis/chronic fatigue syndrome using neuroimaging techniques. PLoS One. 2020;15(4):e0232475. DOI:: 10.1371/journal.pone.0232475 PMID:: 32353033 Study Design:: Systematic review (1994–2019) Sample Size:: 55 included studies Key Findings::

  • Widespread grey/white matter volume changes, cerebral blood flow, EEG, functional connectivity, and cognitive alterations in ME/CFS.
  • Findings are NOT consistent across studies; origins of the anomalies remain unknown. Conclusion:: ME/CFS neuroimaging abnormalities lack a consistent regional/directional pattern — a caution against over-reading any single-lab microstructural finding (including the primary paper). Limitations:: Review (no primary data); heterogeneous methods and case definitions across included studies. Certainty Assessment:: 0.70 raw × 1.00 ME/CFS weight = discounted 0.70

40 Yu et al. 2025 — Post-Infectious vs Gradual-Onset ME/CFS White Matter (Partial Null)

(Yu et al. 2025)

Full Citation:: Yu Q, Kwiatek RA, Del Fante P, Bonner A, Calhoun VD, Bateman GA, Yamamura T, Shan ZY. Distinct white matter alteration patterns in post-infectious and gradual onset chronic fatigue syndrome revealed by diffusion MRI. Scientific Reports. 2025;15:24256. DOI:: 10.1038/s41598-025-09379-z PMID:: 40624094 Study Design:: Cross-sectional diffusion MRI comparing PI- vs GO-ME/CFS vs sedentary-matched HC Key Findings::

  • PI-ME/CFS: higher axial diffusivity (AD) in association/projection fibres, related to worse physical health.
  • GO-ME/CFS: lower AD in corpus callosum, related to worse mental health.
  • NO group differences in fractional anisotropy, mean diffusivity, or radial diffusivity — a partial null constraining which diffusion metric carries the ME/CFS signal. Conclusion:: Distinct AD-alteration patterns by onset type provide neurophysiological evidence of ME/CFS heterogeneity; contrasts the primary paper’s MD/AD/RD findings, underscoring direction heterogeneity across cohorts. Limitations:: Single center (Sunshine Coast); cross-sectional; no FA/MD/RD group effect. Certainty Assessment:: 0.50 raw × 1.00 ME/CFS weight = discounted 0.50

41 Wu et al. 2026 — Cingulum Bundle Injury in CFS (Large-Sample DTI)

(Wu et al. 2026)

Full Citation:: Wu K, Wu Z, Feng S, Zhou T, Ning Y, Li K, Jia H. Microstructural white matter impairments in chronic fatigue syndrome: evidence of segmental injury in the cingulum bundle. Brain Research Bulletin. 2026;234:111671. DOI:: 10.1016/j.brainresbull.2025.111671 PMID:: 41360268 Study Design:: Cross-sectional DTI with 87-tract template + fiber-bundle quantitative analysis + machine learning Sample Size:: n=100 CFS + 100 healthy controls Key Findings::

  • Reduced fractional anisotropy (FA) in left cingulum parolfactory and cingulum frontal-parahippocampal tracts, localised to the middle-posterior cingulum bundle.
  • FA of the two tracts distinguished CFS at 85% accuracy.
  • Recovery of the segmentally disrupted tracts causally associated with fatigue improvement. Conclusion:: Large-n independent replication of cingulum microstructural pathology (paralleling Singh2026DTIDKI cingulum finding), with a machine-learning diagnostic angle. Limitations:: Single center (Beijing); Fukuda-adjacent CFS case definition; cross-sectional. Certainty Assessment:: 0.70 raw × 1.00 ME/CFS weight = discounted 0.70

42 Jahanshahi et al. 2026 — Systematic Review of DWI Microstructure in COVID-19

(Jahanshahi et al. 2026)

Full Citation:: Jahanshahi A, Mohammadi S, Salehi MA, Dolatshahi M, et al. Brain microstructural alterations in COVID-19: a systematic review of diffusion weighted imaging studies. Brain Imaging and Behavior. 2026;20(2):49. DOI:: 10.1007/s11682-026-01084-3 PMID:: 41831107 Study Design:: Systematic review (PubMed/Scopus/Web of Science/EMBASE to Feb 2025) Key Findings::

  • MD and FA most reported; alterations repeatedly in longitudinal fasciculi, thalamic radiations, corpus callosum, fronto-occipital fasciculus, corticospinal tract, uncinate fasciculus.
  • Nearly consistent changes in corona radiata and longitudinal fasciculus.
  • White-matter changes associated with post-COVID psychiatric/cognitive symptoms. Conclusion:: Confirms the primary paper’s superior longitudinal fasciculus finding sits within a broader replicated post-COVID DTI literature. Limitations:: Review; qualitative synthesis (no meta-analysis); heterogeneous study designs. Certainty Assessment:: 0.55 raw × 0.85 long-COVID/post-viral weight = discounted 0.47

43 Huang et al. 2026 — N-PASC White Matter Microstructure (Neuroinflammation)

(Huang et al. 2026)

Full Citation:: Huang C, Zhang X, Ying J, Fontana A, Yang X, West S, Vaska P, Clouston SAP, Luft BJ. White matter microstructural abnormalities in neurological post-acute sequelae of coronavirus disease: imaging signatures consistent with persistent neuroinflammation. Brain, Behavior, & Immunity - Health. 2026;54:101250. DOI:: 10.1016/j.bbih.2026.101250 PMID:: 42112478 Study Design:: Cross-sectional multi-shell diffusion MRI with correlational tractography Sample Size:: n=54 N-PASC (mean 2.7 years) + 26 controls Key Findings::

  • Global and tract-specific white-matter alterations after demographic adjustment.
  • Pronounced bilateral changes to fornix and minor forceps (indirect evidence of axonal injury/demyelination).
  • Diffusion measures associated with fatigue, executive impairment, anosmia, and mood — but NOT brain fog. Conclusion:: Independent (Emory/Stony Brook) long-COVID DTI replication of persistent white-matter microstructural pathology years after infection. Limitations:: Single center; cross-sectional; diffusion cannot specify the underlying biological process. Certainty Assessment:: 0.60 raw × 0.85 long-COVID/post-viral weight = discounted 0.51

44 Arendt et al. 2026 — Frontoinsular-Cingulate DTI in Unvaccinated COVID Survivors (Partial Null)

(Arendt et al. 2026)

Full Citation:: Arendt CT, Klinsing S, Becke E, Fahim M, et al. Subacute frontoinsular-cingulate tract changes in unvaccinated COVID-19 survivors: a tract-based spatial statistics study of diffusion tensor imaging. Brain Research Bulletin. 2026;242:111986. DOI:: 10.1016/j.brainresbull.2026.111986 PMID:: 42235760 Study Design:: Single-center prospective case-control DTI (TBSS) + qT1 + volumetry Sample Size:: n=145 unvaccinated (69 cases, 76 matched seronegative controls) Key Findings::

  • KEY NULL: no significant FA differences between all cases and controls overall.
  • Only older (≥40y) hospitalised subgroup (n=23) showed decreased FA, increased RD, and reduced qT1 in right lateral orbitofrontal/inferior frontal/anterior insular/rostral ACC white matter.
  • Microstructural measures associated with fatigue, depression, poorer sleep, reduced quality of life. Conclusion:: COVID-related microstructural changes are severity- and age-dependent, and may be absent in milder cohorts — a null/negative constraint on the primary paper’s group-wide DTI findings. Limitations:: Single center; subgroup analysis (n=23); TBSS sensitivity limits; unvaccinated only. Certainty Assessment:: 0.60 raw × 0.85 long-COVID/post-viral weight = discounted 0.51

45 Lu et al. 2020 — Cerebral Microstructural Changes in Recovered COVID-19 (3-month)

(Lu et al. 2020)

Full Citation:: Lu Y, Li X, Geng D, Mei N, et al. Cerebral micro-structural changes in COVID-19 patients — an MRI-based 3-month follow-up study. EClinicalMedicine. 2020;25:100484. DOI:: 10.1016/j.eclinm.2020.100484 PMID:: 32838240 Study Design:: Prospective DTI + VBM 3-month follow-up Sample Size:: n=60 recovered COVID-19 + 39 matched controls Key Findings::

  • Higher bilateral grey-matter volume (olfactory cortices, hippocampi, insula).
  • General decline of MD/AD/RD with increased FA in white matter (esp. AD in right corona radiata, external capsule, superior fronto-occipital fasciculus).
  • GMV/MD correlated with memory loss, smell loss, LDH. Conclusion:: Establishes the lower-diffusivity (microstructural reorganisation) pattern in recovered COVID-19 — directly cited by the primary paper as the basis for its COVID-RHC lower-MD/AD/RD caudate finding. Limitations:: 3-month follow-up (short); single center; 2020 cohort (pre-vaccination). Certainty Assessment:: 0.60 raw × 0.85 long-COVID/post-viral weight = discounted 0.51

46 Qin et al. 2024 — White Matter Microstructure in Post-COVID Sleep Disorder (IL-1β link)

(Qin et al. 2024)

Full Citation:: Qin H, Duan G, Zhou K, Qin L, et al. Alteration of white matter microstructure in patients with sleep disorders after COVID-19 infection. Sleep Medicine. 2024;114:109-118. DOI:: 10.1016/j.sleep.2023.12.024 PMID:: 38181582 Study Design:: Case-control DTI + peripheral cytokine assay with 3-month follow-up Sample Size:: n=29 acute COVID with sleep disorder + 27 COVID without + 30 healthy controls Key Findings::

  • Both COVID groups: widespread white-matter microstructural abnormality.
  • Sleep-disorder group: specific changes in right inferior fronto-occipital fasciculus (lower FA/AD, higher RD) and left corticospinal tract, plus higher IL-1β.
  • WM changes and IL-1β normalised by 3 months in the sleep-disorder group. Conclusion:: Indirect biochemical link — post-COVID white-matter microstructural change tracks systemic IL-1β (neuroinflammation) and is partly reversible in mild cases. Limitations:: Acute-phase cohort (not established long COVID); single center; small n. Certainty Assessment:: 0.50 raw × 0.85 long-COVID/post-viral weight = discounted 0.43

47 Rane Levendovszky et al. 2025 — Neuroimaging Biomarkers of PASC (Review)

(Rane Levendovszky et al. 2025)

Full Citation:: Rane Levendovszky S, Patel P, Zhu C, Rutman AM, Basha MM. Neuroimaging biomarkers of post-acute sequelae of coronavirus disease 2019. British Journal of Radiology. 2025;98(1172):1165-1175. DOI:: 10.1093/bjr/tqaf090 PMID:: 40300093 Study Design:: Comprehensive narrative review (University of Washington) Key Findings::

  • Structural MRI: grey-matter volume reductions in frontal/temporal lobes + periventricular white-matter hyperintensities correlating with cognitive deficits.
  • DTI: increased tissue damage and oedema in sagittal stratum and thalamic radiation.
  • rs-fMRI: reduced DMN/executive-network connectivity; PET: frontotemporal hypometabolism, hippocampal/thalamic hypometabolism linked to anosmia/fatigue. Conclusion:: Context/review layer situating the primary paper’s multimodal findings within the broader PASC neuroimaging landscape. Limitations:: Review (no primary data); heterogeneous PASC definitions across studies. Certainty Assessment:: 0.60 raw × 0.85 long-COVID/post-viral weight = discounted 0.51

48 Nielsen et al. 2026 — LDN 30% Responder Rates in FM: FINAL Trial Exploratory Analysis (NULL)

(Nielsen, Vaegter, and Due Bruun 2026)

Full Citation:: Nielsen MJ, Vaegter HB, Due Bruun K. Symptom Response to Low-Dose Naltrexone in Fibromyalgia: An Exploratory Analysis of the Randomized Placebo-Controlled FINAL Trial. Pain Management Nursing. 2026 (online ahead of print). doi:10.1016/j.pmn.2026.07.020 DOI:: 10.1016/j.pmn.2026.07.020 PMID:: 42586891 Study Design:: Exploratory secondary analysis of the randomized placebo-controlled FINAL trial Sample Size:: n=99 women with FM (1:1 LDN 6 mg vs placebo, 12 weeks) Key Findings::

  • No significant between-group differences in 30% responder rates for ANY of six non-pain outcomes: tenderness, fatigue, sleep disturbances, depression, memory problems, stiffness.
  • Highest risk ratio = memory (RR 1.67, 95% CI 0.82–2.95), then sleep (1.28, 0.92–2.64), stiffness (1.26, 0.84–2.89), tenderness (1.16, 0.88–2.67), fatigue (1.10, 0.78–3.13), depression (0.96, 0.92–2.66).
  • The apparent “memory improvement” signal from the primary trial did not reach significance as a 30% responder category. Conclusion:: 30% responder rates for non-pain FM symptoms were similar between LDN and placebo — a NULL result that weakens the earlier memory-benefit hypothesis from the FINAL primary paper. Limitations:: Exploratory/post-hoc; secondary outcomes; wide CIs (underpowered for responder sub-analyses); multiple comparisons; fibromyalgia (not ME/CFS) population. Certainty Assessment:: 0.60 raw × 0.80 fibromyalgia weight = discounted 0.48

49 Due Bruun et al. 2026 — LDN for FM Re-Analysis Suggests Lower Efficacy (Korean J Pain)

(Due Bruun et al. 2026)

Full Citation:: Due Bruun K, Nielsen MJ, Vaegter HB, Blichfeldt-Eckhardt MR, Amris K, Pedersen JR. Low-dose naltrexone for fibromyalgia: a re-analysis suggests lower efficacy than previously reported. The Korean Journal of Pain. 2026;39(1):140–143. DOI:: 10.3344/kjp.25275 Study Design:: Correspondence/re-analysis of FINAL trial data Key Findings::

  • Re-analysis of the FINAL trial data concludes LDN efficacy in FM is lower than previously reported.
  • Authored by the original trial group (Due Bruun, Vaegter, Amris, Blichfeldt-Eckhardt) plus colleagues. Conclusion:: Reinforces the null direction — LDN’s FM benefit is weaker than early positive pilot studies suggested. Limitations:: Brief correspondence format (not a full re-analysis with new data); same underlying trial; fibromyalgia population. Certainty Assessment:: 0.55 raw × 0.80 fibromyalgia weight = discounted 0.44

50 Rodríguez-Freire et al. 2026 — LDN 12-Month RCT in FMS (INNOVA Study) (NULL)

(Rodríguez-Freire et al. 2026)

Full Citation:: Rodríguez-Freire C, Navarrete J, Rozadilla-Sacanell A, Sanabria-Mazo JP, Del Pino-Gaya B, Borràs X, Feliu-Soler A, Luciano JV. Efficacy of Low-Dose Naltrexone in Women With Fibromyalgia Syndrome: A 12-Month Randomised, Double-Blind, Placebo-Controlled Single-Centre Clinical Trial (INNOVA Study). European Journal of Pain. 2026;30(6):e70321. DOI:: 10.1002/ejp.70321 PMID:: 42385209 · PMCID:: PMC13322712 Study Design:: 12-month double-blind RCT Sample Size:: n=98 women with FMS (LDN 4.5 mg n=48, placebo n=50) Key Findings::

  • 3-month pain change: -0.33 (LDN) vs -0.64 (placebo); adjusted between-group difference 0.49 (p=0.236, d=0.19) — NULL.
  • Secondary outcomes (FIQR, DASS-21, MISCI, WHODAS 2.0, GAD-7, PGIC/PSIC) showed minor and inconsistent changes; low similar responder rates (p=0.219–0.954).
  • Adverse events: 68.8% LDN vs 72% placebo, predominantly mild/transient; no treatment-related serious events. Conclusion:: First long-term RCT evidence. LDN (4.5 mg add-on) was well tolerated but showed no clinically meaningful benefit over placebo at short- or long-term follow-up. Limitations:: Single center; add-on design (allowed concomitant medication); fibromyalgia population; responder-rate secondary analyses underpowered. Certainty Assessment:: 0.70 raw × 0.80 fibromyalgia weight = discounted 0.56

51 Due Bruun et al. 2025 — Naltrexone and CPM in FM: FINAL Exploratory Outcomes (NULL for mechanism)

(Due Bruun et al. 2025)

Full Citation:: Due Bruun K, Christensen R, Amris K, Blichfeldt-Eckhardt MR, Bye-Møller L, Henriksen M, Alkjaer T, Toft P, Holsgaard-Larsen A, Vaegter HB. Effect of Naltrexone on Spinal and Supraspinal Pain Mechanisms and Functional Capacity in Women with Fibromyalgia: Exploratory Outcomes from the Randomized Placebo-Controlled FINAL Trial. CNS Drugs. 2025;39(7):685–692. DOI:: 10.1007/s40263-025-01183-7 PMID:: 40214857 · PMCID:: PMC12165890 Study Design:: Secondary mechanistic analysis of FINAL trial Sample Size:: n=99 women with FM (complete-case 45 vs 47) Key Findings::

  • Of 5 outcomes (pain tolerance, temporal summation, CPM, 30-s chair stand, shoulder abduction), only CPM change differed significantly (2.0 kPa, 95% CI 0.4–3.7) favoring LDN.
  • Difference partly explained by CPM decrease in the placebo group.
  • Sensitivity analyses: no association between CPM change and clinical pain improvement → group difference interpreted as random finding. Conclusion:: No evidence LDN acts through measurable changes in central pain-modulation (CPM) to produce clinical benefit — a NULL for the central-mechanism hypothesis. Limitations:: Exploratory; complete-case subset; fibromyalgia population. Certainty Assessment:: 0.60 raw × 0.80 fibromyalgia weight = discounted 0.48

52 Häuser & Fitzcharles 2024 — Is LDN for FM Another Treatment Disappointment? (Editorial)

(Häuser and Fitzcharles 2024)

Full Citation:: Häuser W, Fitzcharles MA. Is low-dose naltrexone for fibromyalgia another treatment disappointment? The Lancet Rheumatology. 2024;6(1):e5–e6. DOI:: 10.1016/S2665-9913(23)00297-7 PMID:: 38258679 Study Design:: Editorial/commentary on the FINAL trial Key Findings::

  • Contextualizes the negative FINAL result against earlier positive pilot studies (Younger 2009/2013, Polo 2019).
  • Raises the question of whether LDN is another over-hyped, ultimately disappointing FM treatment. Conclusion:: Expert editorial endorsing a cautious, null-leaning interpretation of LDN efficacy in FM. Limitations:: Commentary (no new data); fibromyalgia focus. Certainty Assessment:: 0.55 raw × 0.80 fibromyalgia weight = discounted 0.44

53 Ologunowa et al. 2025 — LDN for FM: Systematic Review & Meta-Analysis (NULL between-group)

(Ologunowa et al. 2025)

Full Citation:: Ologunowa A, Otoo MN, Caffrey AR, Buchanan A, Eze UJ, Vyas A. Efficacy of Low-Dose Naltrexone in Treating Patients with Fibromyalgia: Systematic Review and Meta-Analysis. Journal of Pain & Palliative Care Pharmacotherapy. 2025;39(3):363–373. DOI:: 10.1080/15360288.2025.2496526 PMID:: 40272382 Study Design:: Systematic review + meta-analysis (8 studies; search to May 2024) Key Findings::

  • Within-LDN-group pain SMD -1.03 (95% CI -1.25, -0.80; I2=25%) and FM symptom severity -1.02 — significant within-group improvement.
  • BUT no significant between-group difference vs placebo: pain SMD -0.50 (95% CI -1.19, 0.19; I2=91%), symptom severity -0.67 (95% CI -1.67, 0.34; I2=95%). Conclusion:: LDN marginally reduces pain from baseline but is NOT superior to placebo — a NULL between-group result. Limitations:: High heterogeneity; small number of trials; fibromyalgia population; within-group vs between-group contrast central to interpretation. Certainty Assessment:: 0.70 raw × 0.80 fibromyalgia weight = discounted 0.56

54 Vatvani et al. 2024 — LDN for FM: Meta-Analysis with Trial Sequential Analysis (COMPETING/positive)

(Vatvani et al. 2024)

Full Citation:: Vatvani AD, Patel P, Hariyanto TI, Yanto TA. Efficacy and safety of low-dose naltrexone for the management of fibromyalgia: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. The Korean Journal of Pain. 2024;37(4):367–378. DOI:: 10.3344/kjp.24202 PMID:: 39344363 · PMCID:: PMC11450306 Study Design:: Systematic review + meta-analysis with trial sequential analysis (4 RCTs, 222 FM patients) Key Findings::

  • COMPETING/positive: significant pain-score reduction with LDN (MD -0.86, 95% CI -1.20, -0.51, p<0.001, I2=33%) and higher pressure pain threshold (MD 0.17, 95% CI 0.08, 0.25).
  • FIQR and pain catastrophizing scale did not differ between groups.
  • LDN associated with higher vivid dreams and nausea; no significant difference in serious AEs, headache, diarrhea, dizziness. Conclusion:: Contrasts with the null Ologunowa 2025 and FINAL re-analyses; supports modest LDN pain efficacy with a favorable safety profile. Divergent meta-analytic conclusions highlight the dependence of the pooled estimate on included-trial set and methods. Limitations:: Only 4 RCTs; trial sequential analysis; fibromyalgia population; erratum issued (Korean J Pain 2026;39(1):147-149). Certainty Assessment:: 0.65 raw × 0.80 fibromyalgia weight = discounted 0.52

55 Bolton et al. 2019 — Serious Adverse Events of Oral Naltrexone (HARM/SAFETY meta-analysis)

(Bolton et al. 2019)

Full Citation:: Bolton M, Hodkinson A, Boda S, Mould A, Panagioti M, Rhodes S, Riste L, van Marwijk H. Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis. BMC Medicine. 2019;17(1):10. DOI:: 10.1186/s12916-018-1242-0 PMID:: 30642329 · PMCID:: PMC6332608 Study Design:: Systematic review + meta-analysis of harms (89 RCTs, 11,194 participants; doses 3–250 mg) Key Findings::

  • No evidence of increased risk of serious adverse events for naltrexone vs placebo (RR 0.84, 95% CI 0.66–1.06; risk difference -0.01).
  • Only six marginally significant adverse events vs placebo, all mild severity.
  • Results consistent across doses and disease groups (including one FM trial). Conclusion:: Confirms the safety of oral naltrexone; no excess serious harm. Supports the favorable-safety framing of LDN despite null efficacy. Limitations:: Mostly non-FM/ME/CFS populations (alcohol/psychiatric/obesity dominant); LDN-specific dose range underrepresented; fibromyalgia n=1 trial. Certainty Assessment:: 0.75 raw × 0.50 general-population weight = discounted 0.38

56 Gao et al. 2025 — Nanomolar TLR4 Antagonist from (+)-Naltrexone (INDIRECT biochemical link)

(Gao et al. 2025)

Full Citation:: Gao J, Lin C, Deng L, Wang H, Wang X. Nanomolar TLR4 Antagonist CIAC101 Derived from (+)-Naltrexone Blocks Microglial Activation and Methamphetamine Addiction. Journal of Medicinal Chemistry. 2025;68(23):25469–25484. DOI:: 10.1021/acs.jmedchem.5c02596 PMID:: 41265859 Study Design:: Medicinal chemistry + preclinical (in vitro BV-2 microglia + in vivo mouse) Key Findings::

  • (+)-naltrexone enantiomer antagonizes TLR4 without engaging classical opioid receptors; dual-site (C3/N17) optimization produced CIAC101 with nanomolar TLR4 antagonism (~6200-fold more potent than (+)-naltrexone).
  • Blocks LPS-induced NF-κB activation and pro-inflammatory mediators in BV-2 microglia.
  • In vivo: reduces microglial activation and inflammatory gene expression (mPFC, VTA). Conclusion:: Directly establishes the TLR4→microglial anti-neuroinflammatory mechanism hypothesized to underlie LDN’s action, independent of opioid signaling. Context for the null clinical results: even if the TLR4 mechanism is real, it may not translate to measurable FM symptom benefit at LDN doses. Limitations:: Preclinical; no FM/ME/CFS data; methamphetamine model, not chronic pain. Certainty Assessment:: 0.65 raw × 0.40 preclinical weight = discounted 0.26

References

Al Shahab, Shatha, Rawan Al Balushi, Amna Qambar, Ruqayah Abdulla, Maryam Qader, Shooq Abdulla, and Haitham Jahrami. 2025. “Efficiency of Different Supplements in Alleviating Symptoms of ADHD with or Without the Use of Stimulants: A Systematic Review.” Nutrients 17 (9): 1482. https://doi.org/10.3390/nu17091482.
Anas Sohail, Anas, Fernando Ortiz, Teresa Varghese, Stephanie P. Fabara, Arshdeep S. Batth, Darshan P. Sandesara, Ahtesham Sabir, Mahika Khurana, Shae Datta, and Urvish K. Patel. 2021. “The Cognitive-Enhancing Outcomes of Caffeine and l-Theanine: A Systematic Review.” Cureus 13 (12): e20828. https://doi.org/10.7759/cureus.20828.
Arendt, Christof T., Sven Klinsing, Elena Becke, Mena Fahim, et al. 2026. “Subacute Frontoinsular-Cingulate Tract Changes in Unvaccinated COVID-19 Survivors: A Tract-Based Spatial Statistics Study of Diffusion Tensor Imaging.” Brain Research Bulletin 242: 111986. https://doi.org/10.1016/j.brainresbull.2026.111986.
Asch, Ruth H., Chadi G. Abdallah, Richard E. Carson, and Irina Esterlis. 2024. “Challenges and Rewards of in Vivo Synaptic Density Imaging, and Its Application to the Study of Depression.” Neuropsychopharmacology 50 (1): 153–63. https://doi.org/10.1038/s41386-024-01913-3.
Becker, Maxi, Dimitris Repantis, Martin Dresler, and Simone Kühn. 2022. “Cognitive Enhancement: Effects of Methylphenidate, Modafinil, and Caffeine on Latent Memory and Resting State Functional Connectivity in Healthy Adults.” Human Brain Mapping 43 (14): 4225–38. https://doi.org/10.1002/hbm.25949.
Bolton, Monica, Alexander Hodkinson, Shivani Boda, Alan Mould, Maria Panagioti, Sarah Rhodes, Lisa Riste, and Harm van Marwijk. 2019. “Serious Adverse Events Reported in Placebo Randomised Controlled Trials of Oral Naltrexone: A Systematic Review and Meta-Analysis.” BMC Medicine 17 (1): 10. https://doi.org/10.1186/s12916-018-1242-0.
Cambras, Trinitat, Joan Carles Domingo, Ramon Sanmartin-Sentanes, Jose Alegre-Martin, and Jesus Castro-Marrero. 2026. “Association Between Light Exposure Patterns and Multidimensional Health Outcomes in Individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Findings from an Observational Cross-Sectional Cohort Study.” Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08556-6.
Carbone, Manuel Glauco, Giovanni Pagni, Claudia Tagliarini, Icro Maremmani, and Angelo Giovanni Icro Maremmani. 2025. “Caffeine in Aging Brains: Cognitive Enhancement, Neurodegeneration, and Emerging Concerns about Addiction.” International Journal of Environmental Research and Public Health 22 (8): 1171. https://doi.org/10.3390/ijerph22081171.
Cleare, Anthony J., Veronica O’Keane, and John Miell. 2001. “Plasma Leptin in Chronic Fatigue Syndrome and a Placebo-Controlled Study of the Effects of Hydrocortisone.” Clinical Endocrinology 55 (1): 113–19. https://doi.org/10.1046/j.1365-2265.2001.01341.x.
Craighead, Daniel H., Stephen W. Shank, Jinger S. Gottschall, Dennis H. Passe, Bob Murray, Dallas R. Bassett, and Lisa M. Alexander. 2017. “Ingestion of Transient Receptor Potential Channel Agonists Attenuates Exercise-Induced Muscle Cramps.” Muscle & Nerve 56: 379–85. https://doi.org/10.1002/mus.25611.
Czesnik, Dirk, James Howells, Francesco Negro, Hajo Wagenknecht, David Burke, and Hugh Bostock. 2015. “Increased HCN Channel Driven Inward Rectification in Benign Cramp Fasciculation Syndrome.” Brain 138 (Pt 11): 3168–79. https://doi.org/10.1093/brain/awv250.
Domingo, Joan Carles, Federica Battistini, Begona Cordobilla, Maria Cleofe Zaragoza, Ramon Sanmartin-Sentanes, Jose Alegre-Martin, Trinitat Cambras, and Jesus Castro-Marrero. 2024. “Association of Circulating Biomarkers with Illness Severity Measures Differentiates Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Post-COVID-19 Condition: A Prospective Pilot Cohort Study.” Journal of Translational Medicine 22 (1): 343. https://doi.org/10.1186/s12967-024-05148-0.
Due Bruun, Karin, Robin Christensen, Kirstine Amris, Morten Rune Blichfeldt-Eckhardt, L. Bye-Møller, Marius Henriksen, Tine Alkjaer, Palle Toft, Anders Holsgaard-Larsen, and Henrik Bjarke Vaegter. 2025. “Effect of Naltrexone on Spinal and Supraspinal Pain Mechanisms and Functional Capacity in Women with Fibromyalgia: Exploratory Outcomes from the Randomized Placebo-Controlled FINAL Trial.” CNS Drugs 39 (7): 685–92. https://doi.org/10.1007/s40263-025-01183-7.
Due Bruun, Karin, Maria Juul Nielsen, Henrik Bjarke Vaegter, Morten Rune Blichfeldt-Eckhardt, Kirstine Amris, and Julie Roenne Pedersen. 2026. “Low-Dose Naltrexone for Fibromyalgia: A Re-Analysis Suggests Lower Efficacy Than Previously Reported.” The Korean Journal of Pain 39 (1): 140–43. https://doi.org/10.3344/kjp.25275.
Erasmus, Elardus, Francois E. Steffens, Mari van Reenen, B. Christiaan Vorster, and Carolus J. Reinecke. 2019. “Biotransformation Profiles from a Cohort of Chronic Fatigue Women in Response to a Hepatic Detoxification Challenge.” PLoS One 14 (5): e0216298. https://doi.org/10.1371/journal.pone.0216298.
Faber, Chelsea L., Jennifer D. Deem, Bao Anh Phan, Tammy P. Doan, Kayoko Ogimoto, Zaman Mirzadeh, Michael W. Schwartz, and Gregory J. Morton. 2021. “Leptin Receptor Neurons in the Dorsomedial Hypothalamus Regulate Diurnal Patterns of Feeding, Locomotion, and Metabolism.” eLife 10: e63671. https://doi.org/10.7554/eLife.63671.
Fleury, Samantha T., Xuanyi Lin, Peter D. Rios, Christopher Olker, Eun Joo Song, Alejandra Cobos Perez, Cody Fell, et al. 2026. “Encapsulated Leptin-Producing Cells Facilitate Entrainment of Circadian Rhythms in Rodents and Nonhuman Primates.” Advanced Science, e77191. https://doi.org/10.1002/advs.77191.
Gao, Jingwei, Cong Lin, Lehua Deng, Hongshuang Wang, and Xiaohui Wang. 2025. “Nanomolar TLR4 Antagonist CIAC101 Derived from (+)-Naltrexone Blocks Microglial Activation and Methamphetamine Addiction.” Journal of Medicinal Chemistry 68 (23): 25469–84. https://doi.org/10.1021/acs.jmedchem.5c02596.
Garrison, Scott R., Christina S. Korownyk, Michael R. Kolber, G. Michael Allan, Vijaya M. Musini, Ravneet K. Sekhon, and Nicolas Dugré. 2020. “Magnesium for Skeletal Muscle Cramps.” The Cochrane Database of Systematic Reviews 9: CD009402. https://doi.org/10.1002/14651858.CD009402.pub3.
Gerolymos, Cyril, Enzo Saddier, Laurent Boyer, and Guillaume Fond. 2026. “Cognitive and Affective Effects of l-Theanine: A Systematic Review and Meta-Analysis of 31 Randomized Trials.” Molecular Psychiatry. https://doi.org/10.1038/s41380-026-03727-9.
Häuser, Winfried, and Mary-Ann Fitzcharles. 2024. “Is Low-Dose Naltrexone for Fibromyalgia Another Treatment Disappointment?” The Lancet Rheumatology 6 (1): e5–6. https://doi.org/10.1016/S2665-9913(23)00297-7.
Huang, Chao, Xiaoyu Zhang, Jiachen Ying, Ashley Fontana, Xiaohua Yang, Sarah West, Paul Vaska, Sean A. P. Clouston, and Benjamin J. Luft. 2026. “White Matter Microstructural Abnormalities in Neurological Post-Acute Sequelae of Coronavirus Disease: Imaging Signatures Consistent with Persistent Neuroinflammation.” Brain, Behavior, & Immunity – Health 54: 101250. https://doi.org/10.1016/j.bbih.2026.101250.
Jahanshahi, Arash, Sina Mohammadi, Mohammad Amin Salehi, Mahsa Dolatshahi, et al. 2026. “Brain Microstructural Alterations in COVID-19: A Systematic Review of Diffusion Weighted Imaging Studies.” Brain Imaging and Behavior 20 (2): 49. https://doi.org/10.1007/s11682-026-01084-3.
Kahathuduwa, Chanaka N., Sarah Wakefield, Blake D. West, Jessica Blume, Tharaka Lagath Dassanayake, Vajira S. Weerasinghe, and Ann Mastergeorge. 2020. “Effects of l-Theanine-Caffeine Combination on Sustained Attention and Inhibitory Control Among Children with ADHD: A Proof-of-Concept Neuroimaging RCT.” Scientific Reports 10 (1): 13072. https://doi.org/10.1038/s41598-020-70037-7.
Koopmans, Frank, Pim van Nierop, Maria Andres-Alonso, Andrea Byrnes, Tony Cijsouw, Marcelo P. Coba, L. Niels Cornelisse, et al. 2019. “SynGO: An Evidence-Based, Expert-Curated Knowledge Base for the Synapse.” Neuron 103 (2): 217–234.e4. https://doi.org/10.1016/j.neuron.2019.05.002.
Lopate, Glenn, Elizabeth Streif, Matthew Harms, Muhammad Al-Lozi, and Alan Pestronk. 2013. “Cramps and Small-Fiber Neuropathy.” Muscle & Nerve 48 (2): 252–55. https://doi.org/10.1002/mus.23759.
Lu, Yuanqing, Xiang Li, Daoying Geng, Nan Mei, et al. 2020. “Cerebral Micro-Structural Changes in COVID-19 Patients – an MRI-Based 3-Month Follow-up Study.” EClinicalMedicine 25: 100484. https://doi.org/10.1016/j.eclinm.2020.100484.
Maksoud, Reem, Stanley du Preez, Natalie Eaton-Fitch, Kiran Thapaliya, Leighton Barnden, Hélène Cabanas, Donald Staines, and Sonya Marshall-Gradisnik. 2020. “A Systematic Review of Neurological Impairments in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Using Neuroimaging Techniques.” PLoS One 15 (4): e0232475. https://doi.org/10.1371/journal.pone.0232475.
Maughan, Ronald J., and Susan M. Shirreffs. 2019. “Muscle Cramping During Exercise: Causes, Solutions, and Questions Remaining.” Sports Medicine 49 (Suppl 2): 115–24. https://doi.org/10.1007/s40279-019-01162-1.
Mukherjee, Sudip, Snehasish Mandal, José Oberholzer, and Omid Veiseh. 2026. “Type 1 Diabetes and Islet Encapsulation: From Historical Milestones to Cutting-Edge Advances.” Annual Review of Biomedical Engineering 28 (1): 187–217. https://doi.org/10.1146/annurev-bioeng-110824-024435.
Musker, Michael, Alexa McArthur, Zachary Munn, and Ma-Li Wong. 2021. “Circulating Leptin Levels in Patients with Myalgic Encephalomyelitis, Chronic Fatigue Syndrome or Fibromyalgia: A Systematic Review Protocol.” JBI Evidence Synthesis 19 (3): 695–701. https://doi.org/10.11124/JBIES-20-00125.
Nawarathna, Gayani Shashikala, Dinesh Ishara Ariyasinghe, Nadeeka Balasooriya, Asha Fernando, and Tharaka Lagath Dassanayake. 2026. “Effects of l-Theanine-Caffeine Combination on Selective Attention Among Adolescents with Attention-Deficit Hyperactivity Disorder: A Double-Blind, Placebo-Controlled, Crossover Study.” Nutritional Neuroscience, 1–14. https://doi.org/10.1080/1028415X.2026.2659148.
Nielsen, Maria Juul, Henrik Bjarke Vaegter, and Karin Due Bruun. 2026. “Symptom Response to Low-Dose Naltrexone in Fibromyalgia: An Exploratory Analysis of the Randomized Placebo-Controlled FINAL Trial.” Pain Management Nursing. https://doi.org/10.1016/j.pmn.2026.07.020.
Ologunowa, Adaeze, Mary N Otoo, Aisling R Caffrey, Ashley Buchanan, Uchenna J Eze, and Amisha Vyas. 2025. “Efficacy of Low-Dose Naltrexone in Treating Patients with Fibromyalgia: Systematic Review and Meta-Analysis.” Journal of Pain & Palliative Care Pharmacotherapy 39 (3): 363–73. https://doi.org/10.1080/15360288.2025.2496526.
Onwordi, Ellis C., Els F. Halff, Thomas Whitehurst, Ayla Mansur, Marie-Caroline Cotel, Lisa Wells, Hannah Creeney, et al. 2020. “Synaptic Density Marker SV2A Is Reduced in Schizophrenia Patients and Unaffected by Antipsychotics in Rats.” Nature Communications 11 (1): 246. https://doi.org/10.1038/s41467-019-14122-0.
Onwordi, Ellis C., Thomas Whitehurst, Ayla Mansur, Ben Statton, Alex Berry, Marina Quinlan, Declan P. O’Regan, et al. 2021. “The Relationship Between Synaptic Density Marker SV2A, Glutamate and n-Acetyl Aspartate Levels in Healthy Volunteers and Schizophrenia: A Multimodal PET and Magnetic Resonance Spectroscopy Brain Imaging Study.” Translational Psychiatry 11 (1): 393. https://doi.org/10.1038/s41398-021-01515-3.
Osorio-Mendoza, Jazmin, Jana-Thabea Kiehn, Sarah Stenger, Keno O. Heinen, Laura Griewahn, Christiane E. Koch, Undine Haferkamp, et al. 2025. “Regulation of Hedonic Feeding Rhythms by Circadian Clocks in Leptin-Receptive Neurons.” Molecular Metabolism 100: 102221. https://doi.org/10.1016/j.molmet.2025.102221.
Palacios, Natalia, Samantha Molsberry, Kathryn C. Fitzgerald, and Anthony L. Komaroff. 2023. “Different Risk Factors Distinguish Myalgic Encephalomyelitis/Chronic Fatigue Syndrome from Severe Fatigue.” Scientific Reports 13 (1): 2469. https://doi.org/10.1038/s41598-023-29329-x.
Qin, Hongguang, Guofang Duan, Kai Zhou, Li Qin, et al. 2024. “Alteration of White Matter Microstructure in Patients with Sleep Disorders After COVID-19 Infection.” Sleep Medicine 114: 109–18. https://doi.org/10.1016/j.sleep.2023.12.024.
Rane Levendovszky, Swati, Pooja Patel, Chengcheng Zhu, Aaron M. Rutman, and Mahmoud M. Basha. 2025. “Neuroimaging Biomarkers of Post-Acute Sequelae of Coronavirus Disease 2019.” British Journal of Radiology 98 (1172): 1165–75. https://doi.org/10.1093/bjr/tqaf090.
Rodríguez-Freire, Carlos, Jaime Navarrete, Antoni Rozadilla-Sacanell, Juan P Sanabria-Mazo, Beatriz Del Pino-Gaya, Xavier Borràs, Albert Feliu-Soler, and Juan V Luciano. 2026. “Efficacy of Low-Dose Naltrexone in Women with Fibromyalgia Syndrome: A 12-Month Randomised, Double-Blind, Placebo-Controlled Single-Centre Clinical Trial (INNOVA Study).” European Journal of Pain 30 (6): e70321. https://doi.org/10.1002/ejp.70321.
Serrano, Maria-Eleni, Eugene Kim, Marija M. Petrinovic, Federico Turkheimer, and Diana Cash. 2022. “Imaging Synaptic Density: The Next Holy Grail of Neuroscience?” Frontiers in Neuroscience 16: 796129. https://doi.org/10.3389/fnins.2022.796129.
Singh, Tejbir B., Sonya Marshall-Gradisnik, Leighton Barnden, Natalie Eaton-Fitch, Tuan H. Huynh, Maira Inderyas, and Kiran Thapaliya. 2026. “Microstructural Alterations in Brain Tissue of ME/CFS and Long COVID Using Diffusion Tensor Imaging and Diffusion Kurtosis Imaging.” Frontiers in Medicine 13: 1824498. https://doi.org/10.3389/fmed.2026.1824498.
Srinivasan, Mythily, and Paule V. Joseph. 2026. “A Hypothesis Connecting Dysgeusia Due to Defects in ATP-P2X3 Signaling and Fatigue in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Lessons Learned from Long-COVID.” Frontiers in Medicine 13: 1808646. https://doi.org/10.3389/fmed.2026.1808646.
Tang, Qijun, Elizabeth Godschall, Charles D. Brennan, Qi Zhang, Ruei-Jen Abraham-Fan, Sydney P. Williams, Taha Bugra Gungul, et al. 2023. “Leptin Receptor Neurons in the Dorsomedial Hypothalamus Input to the Circadian Feeding Network.” Science Advances 9 (34): eadh9570. https://doi.org/10.1126/sciadv.adh9570.
Thapaliya, Kiran, Sonya Marshall-Gradisnik, Natalie Eaton-Fitch, Zahra Eftekhari, Maira Inderyas, and Leighton Barnden. 2025. “Imbalanced Brain Neurochemicals in Long COVID and ME/CFS: A Preliminary Study Using MRI.” The American Journal of Medicine 138 (3): 567–574.e1. https://doi.org/10.1016/j.amjmed.2024.04.007.
Thapaliya, Kiran, Sonya Marshall-Gradisnik, Maira Inderyas, and Leighton Barnden. 2025. “Altered Brain Tissue Microstructure and Neurochemical Profiles in Long COVID and Recovered COVID-19 Individuals: A Multimodal MRI Study.” Brain, Behavior, & Immunity – Health 50: 101142. https://doi.org/10.1016/j.bbih.2025.101142.
Thapaliya, Kiran, Sonya Marshall-Gradisnik, Donald Staines, and Leighton Barnden. 2020. “Mapping of Pathological Change in Chronic Fatigue Syndrome Using the Ratio of T1- and T2-Weighted MRI Scans.” NeuroImage: Clinical 28: 102366. https://doi.org/10.1016/j.nicl.2020.102366.
———. 2021. “Diffusion Tensor Imaging Reveals Neuronal Microstructural Changes in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” European Journal of Neuroscience 54 (6): 6214–28. https://doi.org/10.1111/ejn.15413.
Vatvani, Akhil D, Priya Patel, Timotius Ivan Hariyanto, and Theo Audi Yanto. 2024. “Efficacy and Safety of Low-Dose Naltrexone for the Management of Fibromyalgia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Trial Sequential Analysis.” The Korean Journal of Pain 37 (4): 367–78. https://doi.org/10.3344/kjp.24202.
Wang, Xin, Najeeb Ali, and Chien-Liang Glenn Lin. 2021. “Emerging Role of Glutamate in the Pathophysiology and Therapeutics of Gulf War Illness.” Life Sciences 280: 119609. https://doi.org/10.1016/j.lfs.2021.119609.
Weigel, Breanna, Natalie Eaton-Fitch, Renée Passmore, Hélène Cabanas, Donald Staines, and Sonya Marshall-Gradisnik. 2021. “A Preliminary Investigation of Nutritional Intake and Supplement Use in Australians with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and the Implications on Health-Related Quality of Life.” Food & Nutrition Research 65. https://doi.org/10.29219/fnr.v65.5730.
Williams, Marshall V., Brandon Cox, William P. Lafuse, and Maria Eugenia Ariza. 2019. “Epstein-Barr Virus dUTPase Induces Neuroinflammatory Mediators: Implications for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Clinical Therapeutics 41 (5): 848–63. https://doi.org/10.1016/j.clinthera.2019.04.009.
Wirth, Klaus J., and Jürgen M. Steinacker. 2025. “The Potential Causes of Myasthenia and Fasciculations in Severely Ill ME/CFS Patients: The Role of Disturbed Electrophysiology.” Frontiers in Physiology 16: 1693589. https://doi.org/10.3389/fphys.2025.1693589.
Wu, Kai, Zhiliang Wu, Siyuan Feng, Tianci Zhou, Yuping Ning, Kuangshi Li, and Hongxiao Jia. 2026. “Microstructural White Matter Impairments in Chronic Fatigue Syndrome: Evidence of Segmental Injury in the Cingulum Bundle.” Brain Research Bulletin 234: 111671. https://doi.org/10.1016/j.brainresbull.2025.111671.
Yu, Qinghao, Richard A. Kwiatek, Peter Del Fante, Alexander Bonner, Vince D. Calhoun, Grant A. Bateman, Takashi Yamamura, and Zack Y. Shan. 2025. “Distinct White Matter Alteration Patterns in Post-Infectious and Gradual Onset Chronic Fatigue Syndrome Revealed by Diffusion MRI.” Scientific Reports 15: 24256. https://doi.org/10.1038/s41598-025-09379-z.
Zagon, Ian S, and Patricia J McLaughlin. 2018. “Intermittent Blockade of OGFr and Treatment of Autoimmune Disorders.” Experimental Biology and Medicine (Maywood) 243 (17-18): 1323–30. https://doi.org/10.1177/1535370218817746.